Press Room
4 September 2024
The convergence of Antibody-Drug Conjugates and Targeted Protein Degraders creates Degrader-Antibody Conjugates: an emerging novel drug modality
STUTTGART, Germany I September 04, 2024 I La Merie Publishing released its newest report with a landscape description and analysis of degrader-antibody conjugate (DAC) stakeholders, platform technologies, development and discovery pipelines and partnering deals from an industry perspective as of…
Read more7 March 2022
Targeted Protein Degradation (TPD) by proteasomal PROTACs & molecular glues, lysosomal LYTACs and autophagic AUTOTACs or ATTECs provides plenty of opportunities to drug undruggable targets
BARCELONA, Spain I March 07, 2022 I La Merie Publishing released today its newest report entitled “Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing”. This report describes…
Read more6 October 2021
Prodrug antibodies and cytokines generated by masking technologies provide plenty of opportunities for founders, investors and partnerships
BARCELONA, Spain I October 06, 2021 I La Merie Publishing announced the release of its newest report about antibody and cytokine prodrugs . The report “Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and…
Read more1 July 2021
Vectorized Antibodies for In Vivo Expression by DNA and mRNA: an emerging new technology
BARCELONA, Spain I July 1, 2021 I La Merie Publishing announced the release of its newest report about in vivo delivery of nucleic acid-encoded antibodies . The report “Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape…
Read more11 June 2019
New report about bispecific antibodies engaging T-cells and NK cells
Business, stakeholder, technology and pipeline anaysis STUTTGART, Germany I June 07, 2019 I La Merie Publishing announces the release of a new report entitled „T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis“. Sample pages…
Read more23 May 2018
TCR Engineered T-Cells 2018: coming out of the shadow to the light
The next two years will give definitive clues about the prospects of this promising treatment modality for solid tumors STUTTGART, Germany I May 23, 2018 I T-Cell Receptors (TCR) and Chimeric Antigen Receptors (CAR) are the cutting edge of adoptive…
Read more12 March 2018
All time high of biologics sales in 2017 driven by cancer antibodies and innovative anti-inflammatory antibodies
STUTTGART, Germany I March 12, 2017 I Global sales of branded recombinant therapeutic antibodies and proteins in the calendar year 2017 reached an all time high of more than US$ 188 bln, as reported by La Merie Publishing. The increase…
Read more25 January 2018
Druggability of intracellular targets: a challenging, but highly rewarded goal for emerging technologies to generate TCR fusion proteins, TCRL antibodies and cell-permeating biologics
STUTTGART, Germany I January 25, 2018 I A tissue-based map of the human proteome suggests that about 75 % are intracellular or secreted targets not accessible for conventional monoclonal antibody and chimeric antigen receptor (CAR) T-cell therapy (Uhlen et al.,…
Read more23 June 2017
mRNA Vaccines and Therapeutics: are you ready to be on the ground floor of the next big new therapeutic modality?
STUTTGART, Germany I June 23, 2017 I Overlooked for many years, RNA languished as the ugly stepchild of nucleic acid vaccine development and was thought to be a poor choice for a therapeutic agent given its short half-life in vivo…
Read more17 March 2017
2016 was another record year of biologics sales with antibodies accounting for two-thirds
STUTTGART, Germany I March 17, 2017 I Sales of branded originator biologics in 2016 continued to reach a record high of US$ 163 bln, a plus of 5.8% compared with the previous year. Growth drivers were therapeutic antibodies for treatment…
Read more25 January 2017
Oncolytic Viruses: a still undervalued technology with strong growth perspectives
STUTTGART, Germany I January 25, 2017 I The acquisition of oncolytic virus company BioVex by Amgen in late 2011 for up to US$ 1 bln has been a game changer for the field of oncolytic viruses, now recognized as a…
Read more19 December 2016
More than ever antibody-drug conjugates generated by new technologies are undergoing clinical proof-of-concept testing
STUTTGART, Germany I December 19, 2016 I Since La Merie Publishing released its last Competitor Analysis report about antibody-drug conjugates in April 2013, the number of ADCs in active clinical development has doubled from 33 in 2013 to 65 at…
Read moreFeatured Reports
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe2023 Sales of Antibodies & Proteins
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
RElated News